Vivimed Labs. (VIVIMEDLAB)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a price-to-book of 0.82, an 18% discount to stated book value of ₹8.35.
• Market cap of ₹63 Cr is low relative to quarterly sales of ₹21 Cr, leaving potential operating leverage if margins recover.
• Price is near the lower end of the 52-week range of ₹4.75–₹29.40, suggesting much of the recent decline is already priced in.

Concerns

• Latest quarter net loss of ₹7 Cr on sales of ₹21 Cr shows severe margin erosion.
• Sales declined 16.79% and profit declined 42.02%, with no visible sign of stabilisation.
• Piotroski F-Score of 2/9 indicates very weak financial health.
• Promoter holding of just 7.77% raises serious questions about management alignment with minority shareholders.

AI Analysis

Vivimed Labs is the kind of stock that looks cheap only if you stop at the balance sheet. At ₹6.85, it trades below a book value of ₹8.35, so the P/B is 0.82. But Ben Graham taught me that a discount to book is meaningless if the business keeps losing money. This company lost ₹7 crore on sales of ₹21 crore in the latest quarter. ROE is -34.27% and ROCE is -8.10%. The return on equity is deeply negative, meaning every rupee of book value invested is being burned. Sales are declining 16.79%, profits are declining 42.02%, and the Piotroski F-score is 2 out of 9. That is not a healthy business; it is a business in distress. I also notice promoter holding is just 7.77%. When promoters own that little, I ask myself: do they have the same incentive as outside shareholders to fix the business? The absence of dividend also means I won't be paid to wait. Debt-to-equity is not available, so I cannot fully assess the balance-sheet risk. A P/E of zero is not attractive—it is just a sign that earnings are absent. The current price may be near the bottom of the 52-week range, and market cap of ₹63 crore is small, but small is not always beautiful. If the company can stabilise sales and get back to breakeven, there could be an operational turnaround. Till I see evidence of that, I would treat this as a possible turnaround situation, not a value investment. I want to see sales stop falling, losses narrow, book value hold steady, and promoter stake increase. Without those signs, a cheap price can become cheaper. In Graham's words, price is what you pay, value is what you get. Here, value remains unproven.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer